DLL1 and cancer: et al., 2013), prevent tumor recurrence (Giordano et al., 2023), and impede autophagy (Giordano et al., 2021) in cancer through downregulation of Notch receptors and ligands, including Notch1, Notch2, Notch4, DLL1, DLL4, and Jagged1.